Table IV.
Comparison of patients with versus without disease progression in the subgroup of patients admitted to the hospital within 5 days of onset of symptoms.*
| Characteristic | No Disease Progression n = 53 (%) | Disease Progression n = 89 (%) | P |
|---|---|---|---|
| Demographic characteristics Age, median (IQR), ys Male sex |
77 (66–84.5) 30 (56.6) |
72 (57.7–84) 54 (60.7) |
0.322 0.633 |
| Comorbidities Chronic pulmonary disease Hypertension Chronic heart disease Diabetes mellitus Cerebrovascular disease Chronic renal disease Solid neoplasm |
12 (22.6) 31 (58.5) 21 (39.6) 10 (18.9) 6 (11.3) 5 (9.4) 5 (9.4) |
9 (10.2) 37 (41.6) 36 (40.4) 26 (29.2) 17 (19.1) 4 (4.5) 10 (11.2) |
0.04 0.051 0.923 0.170 0.224 0.243 0.735 |
| Charlson Comorbidity Index score, median (IQR) | 1 (1–4) | 1 (0.5–2.5) | 0.201 |
| Symptoms before admission Temperature >37.5°C Cough Asthenia Dyspnea Diarrhea Myalgias |
38 (71.7) 15 (28.3) 13 (24.5) 32 (60.4) 5 (9.4) 10 (18.9) |
50 (56.2) 24 (27) 19 (21.3) 26 (19.2) 10 (11.2) 12 (13.5) |
0.065 0.863 0.661 <0.001 0.735 0.391 |
| Clinical features on admission Temperature >37.5°C P/F ratio < 300 Lymphocytes <800 cells/mm3 Platelets <150 × 103/μL D-dimer >1000 ng/ml (n = 176) C-reactive protein, median (IQR), mg/dL C-reactive protein >5 mg/dL Procalcitonin, median (IQR), ng/mL LDH >250 U/L (n = 106) |
26 (49.1) 33 (62.3) 24 (45.3) 16 (30.8) 12/31 (38.7) 6.6 (3.2–11.3) 33 (62.3) 0.09 (0.06–0.2) 26/38 (68.4) |
31 (34.8) 34 (38.2) 32 (36) 28 (31.5) 19/55 (34.5) 3.5 (1.7–5.8) 29 (32.6) 0.09 (0.06–0.2) 37/68 (54.4) |
0.094 0.005 0.271 0.932 0.699 0.005 0.001 0.786 0.159 |
| COVID-19 treatment during hospital stay Early remdesivir (<5 days from symptoms) Corticosteroids Low-molecular-weight heparin Plasma Baricitinib |
61 (68.5) 53 (100) 7 (13.2) 21 (23.6) 4 (4.5) |
29 (54.7) 89 (100) 21 (23.6) 7 (13.2) 6 (11.3) |
0.098 – 0.132 0.132 0.175 |
| Time from symptom onset to the start of remdesivir therapy, median (IQR), d | 4 (2–6) | 5 (3–7) | 0.007 |
IQR = interquartile range; LDH = lactate dehydrogenase; P/F ratio = ratio of inspired oxygen to pulse saturation to fraction of inspired oxygen.